Drug intelligence / Profile preview

tiapride

Development stage
Phase 3
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral, Intramuscular, Intravenous
01

Overview

Tiapride is a selective dopamine D2 and D3 receptor antagonist classified as an atypical neuroleptic agent. It displays high regional selectivity for limbic areas of the brain, with moderate affinity for its target receptors. Unlike other neuroleptics such as haloperidol and risperidone, which affect multiple dopamine receptor subtypes and other neurotransmitter systems, tiapride is more selective in its action. It is primarily used to treat neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, agitation, aggression in the elderly, anxiety disorders (especially in geriatric patients), and sleep disturbances. Its antidyskinetic effects are attributed to its antidopaminergic activity; it also has anxiolytic properties through mechanisms that are not fully understood[1][2][5][6].

Brand names
TiapridalItalpridSereprileTialareadTiarylTiaprimTiaprizalSerepridTiapridex
Other names
tiapride hydrochloridetiapride monohydrochloride
02

Targets

DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on tiapride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tiapride.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call